Based on these findings, we aimed to determine whether CLL patients with lower percentages of nTregs among FOXP3+CD4+ T-cells at the beginning of follow-up would experience a more severe disease progression, specifically in the form of infections requiring hospitalization. The gene discussed is CD4; the disease is B-cell chronic lymphocytic leukemia.